BRUKER CORPORATION (NASDAQ: BRKR)

Q4 2025 Earnings Presentation

February 12, 2026

Frank H. Laukien, President & Chief Executive Officer

Gerald Herman, Executive Vice President & Chief Financial Officer

Joe Kostka, Director, Investor Relations

Safe Harbor Statement

Any statements contained in this presentation which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our fiscal year 2025 and beyond financial outlook, our outlook for reported revenue growth, organic revenue growth, M&A revenue growth contributions, CER currency revenue growth, margin improvements, foreign currency translation revenue impact, EPS, non-GAAP EPS, and CER non-GAAP EPS growth; management's expectations for the impact of foreign currency and acquisitions; the effects of our expanded cost savings initiatives; and for future financial and operational performance and business outlook; future economic conditions. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, the length and severity of any disruption in US academic and government markets, a potential recession, global economic conditions, the impact of supply chain challenges, including inflationary pressures, the impact of geopolitical tensions and any sanctions, the ongoing tensions between the United States and China, tariff and trade policy changes, continued volatility in the capital markets, the impact of interest rates and changing foreign currency exchange rates, the integration and assumption of liabilities of businesses we have acquired or may acquire in the future, our restructuring and cost-control initiatives, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing and outsourcing, competition, dependence on collaborative partners, key suppliers and third party distributors, capital spending and government funding policies, changes in governmental regulations, intellectual property rights, litigation, exposure to foreign currency fluctuations, the impact of foreign currency exchange rates, our ability to service our debt obligations and fund our anticipated cash needs, the effect of a concentrated ownership of our common stock, loss of key personnel, payment of future dividends and other risk factors discussed from time to time in our filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2024, as may be updated by our quarterly reports on Form 10-Q. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.



Q4 2025

Business Update

Q4 2025: Revenue, non-GAAP operating margin and EPS decline on research instruments demand, tariff and FX headwinds in 2025

Q4 2025 Performance; Year-over-Year Changes

- Revenue decrease of $2.4M, or 0.2%
  - Organic decline 5.1%, with BSI and BEST both down 5.1%
  - M&A contribution of +0.8%
  - FX tailwind of +4.1%
- Non-GAAP gross margin: 49.4%, down 310 bps
- Non-GAAP operating margin: 15.7%, down 240 bps
- GAAP EPS: $0.10
- Non-GAAP EPS: $0.59, down 22.4%

  - including FX headwind of $0.03

Q4 Financials

Revenues [$M]



Non-GAAP EPS



Reconciliations of non-GAAP to GAAP financial measures are available in our earnings press release and at the end of this presentation. Y-o-y: year over year. Bps: basis points

FY 2025: Revenue growth driven by M&A and FX; non-GAAP operating margin and EPS down on demand, tariff and FX headwinds

FY 2025 Performance; Year-over-Year Changes

- Revenue increase of $70.1M, or 2.1%
  - Organic revenue down 3.7%, with BSI down 3.5%, BEST down 5.4%
  - M&A contribution of +3.5%
  - FX tailwind of +2.3%
- Non-GAAP gross margin: 49.8%, down 180 bps
- Non-GAAP operating margin: 12.6%, down 280 bps
- GAAP Loss per Share: ($0.15)
- Non-GAAP EPS: $1.83, down 24.1%

  - including FX headwind of $0.12

FY 2025 Financials

Revenues [$M]



Non-GAAP EPS



Reconciliations of non-GAAP to GAAP financial measures are available in our earnings press release and at the end of this presentation. Y-o-y: year over year. Bps: basis points

Bruker Group FY2025 CER Revenue Performance (yoy)

Bruker BIOSPIN Group

- BIOSPIN CER revenue down mid-single digits %
- Growth from lab automation and services offset by weakness in NMR instrumentation
- Weakness in pharma revenue due to 1H-25 bookings softness
- Challenging comparison with four GHz-class NMRs in FY24 vs. two in FY25

Bruker CALID Group

- CALID CER revenue up high-single digits %
- Strong Microbiology & Infection Diagnostics growth, driven by ELITech MDx
- Softness in Mass Spectrometry, but strong orders for recently launched timsOmni and timsMetabo systems, expected to go into revenue in FY26
- Solid molecular spectroscopy growth, driven by Security Detection business

Bruker Group FY2025 CER Revenue Performance (yoy)



Bruker NANO Group

- NANO CER revenue down low single digits %
- Solid growth in Spatial Biology, driven by NanoString
- Robust growth in BioPharma more than offset by declines in Aca/Gov and Industrial
- Semi revenues flat; strong Q4-25 semi orders driven by AI demand

Bruker Energy & Supercon Technologies (BEST) Segment

- BEST CER revenue down mid-single digits %, net of intercompany eliminations
- Soft superconductor demand for clinical MRI
- Strong prior year comparison for Research Instruments (RI)
- Major multi-year orders received in Q4-25 / early Q1-26

Project Accelerate 3.0 (PA3) Expansion

Higher Growth & Margins: Focus on Recurring Revenues

Post-Genomic Era Leadership
- Proteomics/Multiomics
- Spatial Biology
- Post-Genomic Disease Research and Drug Discovery

Novel Microbiology and MDx Opportunities
- Molecular Diagnostics (MDx) with strong placements in FY25
- Microbiology: entering Rapid AST market
- MDx: entering Syndromic Panels market
- Proteomics and Spatial Biology entering LDT/CLIA markets

Automated AI-Labs Market; Security Detection
- Next-gen Automated & Digitized Self-Driving Labs
- Security, defense and airport detection

NanoTools for AI-Tech
- Semi tools for new nodes and advanced packaging

FY2025 BSI Revenue Mix







By Product Type

- >$1.2B after-market (up organically yoy)
- Aftermarket now at ~38% (was 35% in FY24)

By End Market

- >60% of revenue now in PA 3.0 focus areas
- Biopharma, Diagnostics and Semi growth

By Geography

- US biopharma and industrial growth
- US Aca/Gov weak
- 'Rest of APAC' growth
- China declines to <14%

Q4 2025

Financial Update

BRUKER

Q4 2025 Selected Non-GAAP Financial Measures[1]

[$ m, except EPS]	Q4 2025	Q4 2024	Δ
Total Revenues	977.2	979.6	(0.2%)
Gross Profit	483.0	514.2	(6.1%)
Margin (% of revenues)	*49.4%*	*52.5%*	*-310 bps*
SG&A	(230.0)	(233.7)	(1.6%)
(% of revenues)	*23.5%*	*23.9%*	
R&D	(99.6)	(104.4)	(4.6%)
(% of revenues)	*10.2%*	*10.7%*	
Operating Income	153.5	177.5	(13.5%)
Margin (% of revenues)	*15.7%*	*18.1%*	*-240 bps*
Tax Rate	*29.9%*	*32.5%*	*-260 bps*
Net Income[2]	102.1	115.4	(11.5%)
EPS	$0.59	$0.76	(22.4%)
Shares Outstanding	171.7	152.0	13.0%

Comments (year-over-year)

- Revenue decline of 0.2%
- BSI organic revenue down 5.1%; declines in all groups; BEST -5.1% organic revenue decline
- Gross margin decline of 310 bps
- Operating margin decline of 240 bps:
  - Volume -200 bps; Mix -80 bps; Tariffs -90 bps; FX -120 bps; partially offset by cost savings +250 bps
- Non-GAAP EBITDA margin of 18.1%
- Non-GAAP EPS of $0.59, decline of 22.4%, including FX headwind of $0.03
- Shares Outstanding reflects MCP offering

[1]Reconciliations of non-GAAP to GAAP financial measures are available in our earnings press release and at the end of this presentation.

[2]Attributable to Bruker common shareholders, Sum of items may not total due to rounding

Q4-25 Selected Cash Flow And Balance Sheet Measures

[$M]	Q4 2025	Q4 2024	Δ
GAAP Net Income	29.2	13.9	15.3
Depreciation & amortization	58.1	52.9	5.2
Changes in working capital	108.8	1.6	107.2
Other items	33.8	121.6	(87.8)
Operating cash flow	229.8	190.0	39.8
Capital expenditures	(22.6)	(36.7)	14.1
Free cash flow (non-GAAP)	207.2	153.3	53.9

[$M]	Q4 2025	Q4 2024	Δ
Cash, Equivalents & Short-term Investments	$298.8	$183.4	$115.4
Net (Debt)/ Cash	$ (1,572.7)	$ (1,914.0)	-17.8%
WC-to-revenue ratio	0.41	0.42	-2.4%

Comments (year-over-year)

- Q4-25 Operating Cash Flow up ~$40M on improved working capital performance
- Free cash flow up $54M, on higher operating cash flow and lower capital expenditures
- Net debt balances reflect $145M in debt paydown in Q4-25

BRUKER

FY 2025 Selected Non-GAAP Financial Measures[1]

[$ m, except EPS]	FY 2025	FY 2024	Δ
Total Revenues	3,436.5	3,366.4	2.1%
Gross Profit	1,712.0	1,736.9	(1.4%)
Margin (% of revenues)	*49.8%*	*51.6%*	*-180 bps*
SG&A	(884.4)	(844.2)	4.8%
(% of revenues)	*25.7%*	*25.1%*	
R&D	(395.2)	(376.5)	5.0%
(% of revenues)	*11.5%*	*11.2%*	
Operating Income	433.1	518.0	(16.4%)
Margin (% of revenues)	*12.6%*	*15.4%*	*-280 bps*
Tax Rate	*27.1%*	*28.6%*	*150 bps*
Net Income[2]	278.1	360.5	(22.9%)
EPS	$1.83	$2.41	(24.1%)
Shares Outstanding	152.2	149.5	1.8%

Comments (year-over-year)

- Revenue growth of 2.1%
- BSI organic revenue decline of 3.5% with growth in CALID offset by declines in BNANO and BBIO; BEST 5.4% organic revenue decline
- Gross margin decline of 180 bps
- Operating margin decline of 280 bps due to weaker volume leverage, mix, tariffs, FX, partially offset by cost savings
- Improved non-GAAP tax rate of 27.1%
- Non-GAAP EPS of $1.83, decline of 24.1%, including $0.12 FX headwind

[1]Reconciliations of non-GAAP to GAAP financial measures are available in our earnings press release and at the end of this presentation.

[2]Attributable to Bruker, Sum of items may not total due to rounding

FY 2026 Outlook

FY 2026 Financial Outlook (as of February 12th, 2026)

FY 2026 Guidance (year-over-year %s)

Revenue	**$3.57B to $3.60B**
Reported Revenue Growth	**+4% to +5%**
Organic revenue growth	***+1% to +2%***
M&A revenue contribution	***approx. +1.5%***
CER revenue growth	***+2.5% to +3.5%***
Non-GAAP EPS	**$2.10 to $2.15**
Reported EPS Growth	**+15% to +17%**
CER EPS Growth	**+23% to +25%**

Non-GAAP Assumptions & YoY Estimates

- FY26 organic revenue growth of 1–2% includes expected Q1-26 MSD organic revenue decline, primarily due to strong Q1-25 yoy comparison
- FY26 operating margin up 250-300 bps
  - Organic operating margin (OPM) up 300-350 bps
- FX impact from significant decline in USD:
  - Tailwind to revenue ~1.5%
  - Headwind to OPM ~50 bps
  - Headwind to EPS of ~8%, or ~$0.15
- Effective tax rate of 26.5%
- CAPEX: ~$110M
- FX assumptions (rates as of December 31, 2025):
  - EUR = 1.17 USD; CHF = 1.26 USD; JPY = 0.0064 USD

Supplementary Financial Information*

* - For preliminary financial statements, GAAP to Non-GAAP reconciliations, and other supplementary financial information, please refer to our Q4 2025 Earnings Press Release issued February 12th, 2026.